<DOC>
	<DOCNO>NCT00354874</DOCNO>
	<brief_summary>This study evaluate efficacy ( FEV1 ) , safety , tolerability , pharmacodynamics pharmacokinetics single repeat inhaled dos GW642444 . This multi-centre , double-blind , placebo control , dose ascending , four way cross-over study approximately 28 mild moderate asthmatic subject . Key assessment : Efficacy , safety , tolerability , pharmacodynamics pharmacokinetics assess measurement FEV1 , blood pressure , heart rate , 12-lead ECGs , clinical laboratory test , collection adverse event ( AE ) information blood sample .</brief_summary>
	<brief_title>Investigation Of A New Medication ( GW642444 ) In Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Female subject must nonchildbearing ( i.e. , surgically sterilise postmenopausal ) . Nonsmokers least 6 month . Stable asthma . Exclusion criterion : Abnormal finding heart monitoring assessment . Lower respiratory tract infection within 4 week , upper respiratory tract within 2 week study . Currently take dos fluticasone propionate 500mcg/day . Unstable asthma medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GW642444 asthmatic subject safety tolerability PD PK</keyword>
</DOC>